Combination therapy with paclitaxel and gemcitabine after platinum‐based chemotherapy in patients with advanced urothelial cancer
Author:
Affiliation:
1. Department of Urology School of Medicine University of Occupational and Environmental Health Kitakyushu FukuokaJapan
2. Munakata Suikokai General Hospital Fukutsu Fukuoka Japan
Publisher
Wiley
Subject
Urology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14616
Reference18 articles.
1. Epidemiology and Risk Factors of Urothelial Bladder Cancer
2. What is new in non-muscle-invasive bladder cancer in 2016?
3. Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies
4. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids;Frontiers in Oncology;2024-03-13
2. Gemcitabine/Nab‐Paclitaxel versus Gemcitabine/Carboplatin for Advanced Urothelial Carcinoma;BJU International;2023-11-27
3. Effects of Camrelizumab Combined with First-Line Chemotherapy on Serum SCC, VEGF Levels, and Adverse Reactions in Patients with Advanced Squamous Cell Carcinoma of the Lung;Computational Intelligence and Neuroscience;2022-11-18
4. Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy;International Journal of Molecular Sciences;2022-10-11
5. Targeted Inhibition of O-Linked β-N-Acetylglucosamine Transferase as a Promising Therapeutic Strategy to Restore Chemosensitivity and Attenuate Aggressive Tumor Traits in Chemoresistant Urothelial Carcinoma of the Bladder;Biomedicines;2022-05-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3